COMPANY ANNOUNCEMENT - No. 21-2021 -
BIRKERØD,
In Q1-Q3, 2021, ViroGates’ revenue was TDKK 5,063, increasing by 66% compared to the same period last year. The increase was driven by new customers and higher sales from clinically relevant products in
The net effect of the COVID-19 pandemic remains uncertain for
Financial results in Q1-Q3, 2021
The financial results in Q1-Q3, 2021, continued to show an improvement compared to last year despite lower revenue in Q3 due to customer summer holidays (Q1-Q3, 2020 results in brackets):
- Revenue increased by 66% to TDKK 5,063 (TDKK 3,055)
- Operating expenses increased by 8% to TDKK -19,518 (TDKK -18,029)
- Operating loss decreased by -3% to TDKK -14,455 (TDKK -14,974)
- Net loss decreased by -5% to TDKK -13,641 (TDKK -14,293)
- Cash and cash equivalents at the end of the period amounted to TDKK 17,475 (TDKK 38,028)
Business highlights in Q1-Q3, 2021
- Welcomed six new clinical routine customers – four hospitals in
Greece , one hospital inSpain and one hospital inItaly – although no new customers were announced in Q3 -
Positive results from the SAVE-MORE trial were published in Nature Medicine, showing an improvement in overall clinical outcome by 64% in hospitalized patients with COVID-19 pneumonia, followed by a
European Medicines Agency evaluation of a label extension of anakinra (Q3) - CE-IVD validated suPARnostic® TurbiLatex on the Siemens Healthineers Atellica® and Abbott Alinity platforms (Q1/Q2)
- Announced a delay in the development and launch of the suPARnostic® POC+ product (Q1)
This announcement is a summary and should be read in conjunction with ViroGates’ Interim Report for Q1-Q3, 2021, published on
For further information, please contact:
CEO,
Tel. (+45) 2226 1355, email: jk@virogates.com
Certified Advisor:
Västra Hamnen Corporate Finance
Per Lönn
Tel. (+46) 40 200 250, email: per.lonn@vhcorp.se
Conference call to present the Q1-Q3 2021 report
Västra Hamnen Corporate Finance hosts the first on
https://register.gotowebinar.com/register/8438786246686366733
https://hcandersencapital.dk/event/virogates-praesentation-af-q3-kvartalsregnskabet
About
The company was founded in 2000. Headquartered in
About suPAR and suPARnostic®
suPAR is the biomarker detected by ViroGates’ suPARnostic® products and is a protein in plasma, measurable in every human being. suPAR is considered a general risk status biomarker indicating disease presence, disease severity and progression, organ damage and mortality risk across disease areas such as cardiovascular diseases, kidney diseases, type 2 diabetes, cancer, etc. Strong scientific evidence from more than 600 clinical trials and studies show that the higher the level of suPAR, the worse the prognosis for the patient.
The suPARnostic® products can be used to support healthcare professionals in making clinical decisions on hospitalization or discharge of acute care patients. The increasing demands on health systems globally and tightening healthcare budgets necessitate efficiency improvements and innovative solutions in hospitals. The use of suPAR in clinical routine in emergency departments can improve patient care and reduce healthcare costs by increasing the number of discharges by up to 34% and reducing the average hospital length-of-stay by up to 6% without affecting mortality. suPARnostic® TurbiLatex is currently available on Roche Diagnostics’ cobas® instruments, Siemens Healthineers ADVIA® XPT and Atellica® instruments and the Abbott Labs Architect™ and Alinity™ instruments.
Disclosure regulation
Prospects about the future reflect
Contacts
Jakob Knudsen , CEO, +45 2226 1355, jk@virogates.com
Attachments
ViroGates Interim Report Q1-Q3 2021.pdf
© Ritzau Denmark, source